Methods to treat one or all of the defined etiologies of female sexual dysfunction
First Claim
1. A compound for the topical manual application directly to the female clitoris containing Vardenafil, L-arginine and;
- Menthol or any cooling agent listed below, having a concentration of less than 0.5% and greater than 0.01%;
a) wherein said cooling agent includes menthol b) wherein said cooling agent includes peppermint oil;
c) wherein said cooling agent includes cornmint oil. d) wherein said cooling agent includes Eucalypus oil. e) wherein said cooling agent includes Citronella oil. f) wherein said cooling agent includes Camphor oil. g) wherein said cooling agent includes Cinnamon oil. h) Wherein said cooling agent essentially comprises Menthol i) wherein said cooling agent essentially comprises peppermint oil. j) wherein said cooling agent essentially comprises cornmiint oil. k) wherein said cooling agent essentially comprises Eucalyptus'"'"' oil. l) wherein said cooling agent essentially comprises Citronella oil. m) wherein said cooling agent essentially comprises Camphor oil. n) wherein said cooling agent essentially comprises Cinnamon oil. o) wherein said cooling agent includes a menthol analog or derivative with cooling properties;
Menthol Analogs and Derivatives (+)-neo-Menthol Menthone (+)-iso-Menthone Menthyl acetate Menthyl isovalerate (−
)-Menthyl lactate para-menth-1-en-3ol Piperitone (−
)-Menthol ethylene glycol carbonate (−
)-Menthol 1-and 2-propylene glycol carbonate (−
)-Menthone 1,2-glycerol ketal (+)-Menthone 1,2-glycerol ketal mono-Menthyl succinate
1 Assignment
0 Petitions
Accused Products
Abstract
The U.S. Food and Drug Administration defines the four separate components of Female Sexual Dysfunction (FSD) to be decreased sexual desire, decreased sexual arousal, dyspareunia (pain with intercourse), and persistent difficulty in achieving or inability to achieve orgasm (anorgasmia). To establish a diagnosis of FSD, these components must be associated with personal distress, as determined by the affected woman. A topical combination of menthol/L-arginine and the specific 5-PDE inhibitor vardenafil can be used to treat any of the defined components, or a combination of two or more of the defined components of FSD, as a safe, first-line therapy for FSD.
-
Citations
18 Claims
-
1. A compound for the topical manual application directly to the female clitoris containing Vardenafil, L-arginine and;
Menthol or any cooling agent listed below, having a concentration of less than 0.5% and greater than 0.01%;
a) wherein said cooling agent includes menthol b) wherein said cooling agent includes peppermint oil;
c) wherein said cooling agent includes cornmint oil. d) wherein said cooling agent includes Eucalypus oil. e) wherein said cooling agent includes Citronella oil. f) wherein said cooling agent includes Camphor oil. g) wherein said cooling agent includes Cinnamon oil. h) Wherein said cooling agent essentially comprises Menthol i) wherein said cooling agent essentially comprises peppermint oil. j) wherein said cooling agent essentially comprises cornmiint oil. k) wherein said cooling agent essentially comprises Eucalyptus'"'"' oil. l) wherein said cooling agent essentially comprises Citronella oil. m) wherein said cooling agent essentially comprises Camphor oil. n) wherein said cooling agent essentially comprises Cinnamon oil. o) wherein said cooling agent includes a menthol analog or derivative with cooling properties;
Menthol Analogs and Derivatives (+)-neo-Menthol Menthone (+)-iso-Menthone Menthyl acetate Menthyl isovalerate (−
)-Menthyl lactatepara-menth-1-en-3ol Piperitone (−
)-Menthol ethylene glycol carbonate(−
)-Menthol 1-and 2-propylene glycol carbonate(−
)-Menthone 1,2-glycerol ketal(+)-Menthone 1,2-glycerol ketal mono-Menthyl succinate - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
Specification